Introduction: Many limitations in the Brazilian public health system make the patient’s journey with HER2+breastcancer and the access to better treatments hard. In the scenery in which all the economic resources of the country are limited, the incorporation of health technologies proves to be a challenge.

Purpose: To identify the main issues regarding the patient’s journey with HER2+ breast cancer in Brazil’s public health system and, in this context, demonstrate the incorporation process of a new drug technology for this condition, proposing a critical assessment of the topic.

Results: Pertuzumab has proved to be an important option for the treatment of HER2+ breast cancer. The society and scientific community’s engagement have proved to be extremely influent so the incorporation of this therapy in the Brazilian public health system would be possible. Pertuzumab’s incorporation process has properly respected the concepts encompassed by the Brazilian Health Technology Assessment. However, after the positive deliberation regarding pertuzumab’s incorporation process, it has not been registered its supply to the population, suggesting a delay in the predetermined due date by the law.

Conclusion: The incorporation of innovative technologies to Brazilian public health system became a way to provide access to society, if they sustainably fit inthe system. The assessment of this abstract has allowed a deeper knowledge regarding the reality of the journey’s patient in the public health system, the importance of the Brazilian Health Technology Assessment, of the incorporation and transfer of technologies and the society’s engagement in this scenery.